BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

108 related articles for article (PubMed ID: 29346503)

  • 1. p53β: a new prognostic marker for patients with clear-cell renal cell carcinoma from 5.3 years of median follow-up.
    Zhang H; Zhao Y; Sun P; Zhao M; Su Z; Jin X; Song W
    Carcinogenesis; 2018 Mar; 39(3):368-374. PubMed ID: 29346503
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Expression of p53 isoforms in renal cell carcinoma.
    Song W; Huo SW; Lü JJ; Liu Z; Fang XL; Jin XB; Yuan MZ
    Chin Med J (Engl); 2009 Apr; 122(8):921-6. PubMed ID: 19493415
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of p53β in the inhibition of proliferation of gastric cancer cells expressing wild-type or mutated p53.
    Ji W; Ma J; Zhang H; Zhong H; Li L; Ding N; Jiao J; Gao Z
    Mol Med Rep; 2015 Jul; 12(1):691-5. PubMed ID: 25695150
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The role of p53 isoforms' expression and p53 mutation status in renal cell cancer prognosis.
    Knezović Florijan M; Ozretić P; Bujak M; Pezzè L; Ciribilli Y; Kaštelan Ž; Slade N; Hudolin T
    Urol Oncol; 2019 Sep; 37(9):578.e1-578.e10. PubMed ID: 30948335
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Modulation of p53β and p53γ expression by regulating the alternative splicing of TP53 gene modifies cellular response.
    Marcel V; Fernandes K; Terrier O; Lane DP; Bourdon JC
    Cell Death Differ; 2014 Sep; 21(9):1377-87. PubMed ID: 24926616
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chromophobe renal cell carcinoma (RCC): oncological outcomes and prognostic factors in a large multicentre series.
    Volpe A; Novara G; Antonelli A; Bertini R; Billia M; Carmignani G; Cunico SC; Longo N; Martignoni G; Minervini A; Mirone V; Simonato A; Terrone C; Zattoni F; Ficarra V; ;
    BJU Int; 2012 Jul; 110(1):76-83. PubMed ID: 22044519
    [TBL] [Abstract][Full Text] [Related]  

  • 7. p53 mutant breast cancer patients expressing p53γ have as good a prognosis as wild-type p53 breast cancer patients.
    Bourdon JC; Khoury MP; Diot A; Baker L; Fernandes K; Aoubala M; Quinlan P; Purdie CA; Jordan LB; Prats AC; Lane DP; Thompson AM
    Breast Cancer Res; 2011 Jan; 13(1):R7. PubMed ID: 21251329
    [TBL] [Abstract][Full Text] [Related]  

  • 8. p53-expression in patients with renal cell carcinoma correlates with a higher probability of disease progression and increased cancer-specific mortality after surgery but does not enhance the predictive accuracy of robust outcome models.
    Morshaeuser L; May M; Burger M; Otto W; Hutterer GC; Pichler M; Klatte T; Wild P; Buser L; Brookman-May S
    Urol Oncol; 2018 Mar; 36(3):94.e15-94.e21. PubMed ID: 29221641
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Gelsolin, NF-κB, and p53 expression in clear cell renal cell carcinoma: Impact on outcome.
    Kankaya D; Kiremitci S; Tulunay O; Baltaci S
    Pathol Res Pract; 2015 Jul; 211(7):505-12. PubMed ID: 25908108
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Value of p53 as a prognostic marker in histologic subtypes of renal cell carcinoma: a systematic analysis of primary and metastatic tumor tissue.
    Zigeuner R; Ratschek M; Rehak P; Schips L; Langner C
    Urology; 2004 Apr; 63(4):651-5. PubMed ID: 15072872
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High expression of Mucin13 associates with grimmer postoperative prognosis of patients with non-metastatic clear-cell renal cell carcinoma.
    Xu Z; Liu Y; Yang Y; Wang J; Zhang G; Liu Z; Fu H; Wang Z; Liu H; Xu J
    Oncotarget; 2017 Jan; 8(5):7548-7558. PubMed ID: 27911274
    [TBL] [Abstract][Full Text] [Related]  

  • 12. DNA methylation status defines clinicopathological parameters including survival for patients with clear cell renal cell carcinoma (ccRCC).
    Evelönn EA; Degerman S; Köhn L; Landfors M; Ljungberg B; Roos G
    Tumour Biol; 2016 Aug; 37(8):10219-28. PubMed ID: 26831665
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Clinical significance and expression of PUMA, MCL-1, and p53 in human renal cell carcinoma and para-carcinoma tissues.
    Xia HB; Cui HW; Su L; Zhang ZH; Yang XY; Ning SQ; Su XL
    Genet Mol Res; 2017 Jul; 16(3):. PubMed ID: 28692117
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intratumoral expression of programmed death ligand 1 (PD-L1) in patients with clear cell renal cell carcinoma (ccRCC).
    Abbas M; Steffens S; Bellut M; Eggers H; Großhennig A; Becker JU; Wegener G; Schrader AJ; Grünwald V; Ivanyi P
    Med Oncol; 2016 Jul; 33(7):80. PubMed ID: 27317388
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Combined p53 and MDM2 biomarker analysis shows a unique pattern of expression associated with poor prognosis in patients with renal cell carcinoma undergoing radical nephrectomy.
    Noon AP; Polański R; El-Fert AY; Kalirai H; Shawki H; Campbell F; Dodson A; Eccles RM; Lloyd BH; Sibson DR; Coupland SE; Lake SL; Parsons K; Vlatković N; Boyd MT
    BJU Int; 2012 Apr; 109(8):1250-7. PubMed ID: 21756282
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High expression of interleukin-11 is an independent indicator of poor prognosis in clear-cell renal cell carcinoma.
    Pan D; Xu L; Liu H; Zhang W; Liu W; Liu Y; Fu Q; Xu J
    Cancer Sci; 2015 May; 106(5):592-7. PubMed ID: 25702890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. miR-566 functions as an oncogene and a potential biomarker for prognosis in renal cell carcinoma.
    Pan X; Quan J; Li Z; Zhao L; Zhou L; Jinling X; Weijie X; Guan X; Li H; Yang S; Gui Y; Lai Y
    Biomed Pharmacother; 2018 Jun; 102():718-727. PubMed ID: 29604591
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Promoter hypermethylation profile of kidney cancer with new proapoptotic p53 target genes and clinical implications.
    Christoph F; Weikert S; Kempkensteffen C; Krause H; Schostak M; Köllermann J; Miller K; Schrader M
    Clin Cancer Res; 2006 Sep; 12(17):5040-6. PubMed ID: 16951219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. MDM2 SNP309 polymorphism as risk factor for susceptibility and poor prognosis in renal cell carcinoma.
    Hirata H; Hinoda Y; Kikuno N; Kawamoto K; Suehiro Y; Tanaka Y; Dahiya R
    Clin Cancer Res; 2007 Jul; 13(14):4123-9. PubMed ID: 17634539
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Body mass index and survival in patients with renal cell carcinoma: a clinical-based cohort and meta-analysis.
    Choi Y; Park B; Jeong BC; Seo SI; Jeon SS; Choi HY; Adami HO; Lee JE; Lee HM
    Int J Cancer; 2013 Feb; 132(3):625-34. PubMed ID: 22610826
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.